Retinol Binding Protein 4 Promotes Chondrocyte and Osteoclast Differentiation

Retinol-binding protein 4 (RBP4), an adipokine secreted by adipose tissues, has been implicated in metabolic inflammation and insulin resistance. Type 2 diabetes (T2D) is a recognized risk factor for osteoarthritis, with both conditions characterized by chronic low-grade inflammation, suggesting potential links between metabolic disorder and joint degeneration. This study aimed to investigate whether inflammatory and metabolic stresses regulate RBP4 expression and function in joint-related cells. Murine immature chondrocyte cells (iMACs) and the mouse AT805 teratocarcinoma cell line, clone 5, that differentiates into chondrogenic cells (ATDC5), were used as in vitro models for chondrocyte cells. <i>Rbp4</i> mRNA expression increased during differentiation of iMACs, with 3.6- and 2.2-fold elevations observed on days 7 and 14, respectively (<i>p</i> < 0.01 vs. undifferentiated controls). Inflammatory stimulation with interleukin-6 (IL-6) significantly increased <i>Rbp4</i> mRNA expression in ATDC5 cells (<i>p</i> < 0.05 vs. vehicle), along with elevated expression of catabolic and inflammatory mediators, including monocyte chemoattractant protein-1 (<i>Mcp1</i>), cyclooxygenase-2 (<i>Cox2</i>), and matrix metalloproteinase-3 (<i>Mmp3</i>) (<i>p</i> < 0.05 vs. vehicle). Pharmacological inhibition of RBP4 using fenretinide (FEN) attenuated chondrogenic differentiation marker expression, reduced glycosaminoglycan synthesis during chondrogenic differentiation, and mitigated high-glucose-induced catabolic responses, as indicated by reduced <i>Mcp2</i> (<i>p</i> = 0.04) and <i>Mmp13</i> (<i>p</i> = 0.01) expression in ATDC5 cells treated with FEN compared with cells treated with the vehicle under high-glucose conditions. Furthermore, in RAW 264.7 cells, a murine macrophage cell line commonly used as an in vitro model for osteoclastogenesis, FEN significantly reduced the expression of osteoclast differentiation markers, dendritic cell-specific transmembrane protein (<i>DC-Stamp</i>), nuclear factor of activated T-cells, cytoplasmic 1 (<i>Nf-atc1</i>), cathepsin k (<i>Cath.k</i>), and tartrate-resistant acid phosphatase (<i>Trap</i>) under osteoclastogenic conditions (<i>p</i> < 0.01 vs. vehicle). Collectively, these findings suggest that RBP4 functions as a metabolic-inflammatory mediator influencing both cartilage and bone-remodeling processes. This study reveals a previously unrecognized role of RBP4 in regulating osteoclast-associated pathways. Targeting RBP4 may, therefore, represent a promising therapeutic strategy for delaying or preventing osteoarthritis progression, particularly in metabolically compromised conditions.